Clinical trial on bloodletting therapy in knee osteoarthritis

A clinical study to evaluate the effect of siravedha on knee osteoarthritis and pro-inflammatory biomarkers - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/067240

Enrollment

Registered

2024-05-13

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Grade 2 knee osteoarthritis patients as per Kellgren and Lawrence classification system

Exclusion criteria

Exclusion criteria: Rheumatoid arthritis, Gouty arthritis, osteomyelitis and septic arthritis of knee joints, local infection or skin diseases on the proposed site of Siravedha, Patients suffering from cardiovascular diseases, HIV, hepatitis, diabetes mellites, hypertension, Anemia and bleeding disorders. Contraindications for Siravedha. History of trauma to knee joint. History of surgical intervention on knee joint.

Design outcomes

Primary

Measure	Time frame
Change in symptoms of knee osteoarthritis. Change in WOMAC scale. Change in Pro-inflammatory biomarkers in blood after Siravedha in knee osteoarthritis.Timepoint: 21days	—

Secondary

Measure	Time frame
Identification of type of the Prakriti most vulnerable to Knee Osteoarthritis. Change in quality of life of the patient.Timepoint: 3 months	—

Countries

India

Contacts

Public ContactDr Manorma Singh

National institute of ayurveda, jaipur

sumanhp2006@gmail.com9418159666

Outcome results